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Asthma is characterized by both chronic inflammation and airway remodeling. Remodeling - the structural changes
seen in asthmatic airways - is pivotal in the pathogenesis of the disease. Although significant advances have been
made recently in understanding the different aspects of airway remodeling, the exact biology governing these
changes remains poorly understood. There is broad agreement that, in asthma, increased airway smooth muscle
mass, in part due to smooth muscle hyperplasia, is a very significant component of airway remodeling. However,
significant debate persists on the origins of these airway smooth muscle cells. In this review article we will explore
the natural history of airway remodeling in asthma and we will discuss the possible contribution of progenitors,
stem cells and epithelial cells in mesenchymal cell changes, namely airway smooth muscle hyperplasia seen in the
asthmatic airways.
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The immunopathological features of asthma include
chronic airway inflammation and airway remodeling [1].
Over the past few decades, the research into the patho-
physiology and treatment of asthma has been primarily
focused on the inflammatory side of the disease with
most new therapies targeting various aspects of inflam-
mation. Despite this, there persists a huge unmet need,
especially for patients with severe asthma who have per-
sistent debilitating symptoms and increased morbidity
and mortality despite maximum anti-inflammatory ther-
apy. Severe asthmatics account for 5 to 10% of asthma
sufferers and are responsible for more than 50% of
asthma related costs [2,3].
Airway remodeling, a collective term describing the
wide range of histopathological structural changes seen in
the asthmatic airway wall, has been recognized for almost
a century; however, significant gaps still remain in our
understanding of various aspects, including its natural
history, etiology, molecular and cellular basis and, more
importantly, its clinical and physiological relevance. Air-
way remodeling is characterized by increased airway
smooth muscle (ASM) mass, sub-epithelial fibrosis, goblet* Correspondence: ceb17@le.ac.uk
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reproduction in any medium, provided the orcell hyperplasia, sub-mucosal mucus gland hyper-
trophy, neoangiogenesis, an abnormally fragile epithe-
lium and an increased number of activated fibroblasts
and myofibroblasts with subsequent increased depos-
ition of extracellular matrix proteins [4-7]. Although
most of the aforementioned characteristics of airway
remodeling contribute to the airway narrowing seen in
asthma, increased ASM mass, due to both ASM hyper-
plasia and hypertrophy, and sub-epithelial fibrosis, are
the most critical. ASM mass is a major component re-
sponsible for bronchoconstriction of airways in re-
sponse to stimuli and, together with sub-epithelial
myofibroblast hyperplasia, is the major determinant of
persistent airflow obstruction [8,9]. Myofibroblasts are
contractile mesenchymal cells located in the sub-
mucosa between the airway smooth muscle bundle and
the epithelium. In addition to secreting extracellular
matrix proteins, myofibroblasts have similar character-
istics and function to ASM and probably represent part
of the spectrum of plasticity of mesenchymal cells
(fibroblasts ⇔ myofibroblasts ⇔ ASM).
In this review we will attempt to explore the under-
lying mechanisms leading to increased ASM mass in the
asthmatic airways and the possible implications in devel-
oping new asthma therapies.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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remodelling?
Before attempting to unfold the origins of increased
ASM mass in asthma it is important to try and under-
stand the natural history of airway remodeling, including
its initiation, its progress and, importantly, its relation to
airway inflammation. The airway is exposed to a number
of potential stimuli including pathogens, pollutants and
allergens. The role of these stimuli in the genesis of air-
way remodeling, particularly with regard to ASM mass,
is poorly understood. In an allergen challenge study of
asthmatics who had bronchial biopsies pre-, and one
and seven days post-challenge, sub-epithelial fibroblast
number and activation, and reticular basement mem-
brane (RBM) thickening, increased and persisted over
the seven days and was associated with increased airway
hyper-responsiveness. In contrast, inflammation observed
at day one had resolved by day seven [10]. This suggests
that remodeling occurs in response to allergen chal-
lenge; is related to airway dysfunction, might require in-
flammation for its initiation, but is not dependent upon
persistent inflammation.
Viruses are the most common cause of asthma exa-
cerbations and are, therefore, possibly involved in the in-
duction of remodeling although the evidence is scanty.
Rhinovirus in vitro can promote the release of matrix pro-
teins from cultured ASM suggesting it may influence re-
modeling [11]. Another surprising factor that influences
remodeling is the pure mechanical force that is generated
by constriction of airways. Bronchoconstriction induced
by using the indirect ASM spasmogen methacholine, was
found to promote RBM thickening [12]. However, whether
any of these stimuli affect ASM mass is unknown.
The natural history of airway remodeling is unknown.
Whether a single or a few airway insults over weeks to
months, versus several repeated insults over many years,
are required to cause airway remodeling is unclear.
What is clear, interestingly, is that changes in RBM
thickness and ASM mass occur early in the natural his-
tory of asthma. Increased RBM thickness is present in
preschool children with wheeze, and only those who also
show signs of airway remodeling are subsequently diag-
nosed with asthma at school age [13,14].
The dynamic relationship between inflammation and
remodeling is poorly understood. The classical paradigm
was that repeated inflammation of the airways, mainly
due to exaggerated T-helper type-2 immune response,
leads to defective repair and remodeling. However, there
is increasing evidence discrediting this simple concept.
In children with established severe disease, RBM thick-
ening and increased ASM mass are present and dissoci-
ated from inflammation [15]. Similarly, Cokugras et al.
reported in 10 children with moderate asthma evidence
of remodeling preceding inflammation [16]. All theseobservations raise important questions about the time-
scales required for the establishment of airway remodel-
ing and the timing of interventions to alter the natural
history of the disease.
What are the origins of increased ASM mass in asthma?
In humans, ASM is a normal component of both large
and small airways. The exact physiological function of
ASM has always been a controversial issue with some
claiming that it plays a role in maintaining bronchial
tone and lung ventilation, while others consider it a ves-
tigial ruminant with no function akin to the intestinal
appendix [17].
The increase in ASM volume in asthma is caused by
both hyperplasia and hypertrophy [8,18]. Although there
is general agreement that ASM hyperplasia seems to be
more dominant and significant, its origin remains uncer-
tain. These new ASM cells might be a consequence of
increased proliferation and/or prolonged survival of pre-
existing ASM; or could result from recruitment of non-
ASM cells that would transform and differentiate into
ASM. These potential ASM progenitors include true
multipotent mesenchymal progenitor and stem cells,
either located within airway tissues or derived from
peripheral blood, and airway epithelial cells which can
migrate and transform into a mesenchymal cell phe-
notype through a biological process called epithelial-
mesenchymal transition (EMT) (Figure 1).
ASM proliferation and survival
In biology, hyperplasia of any tissue is usually caused
by the increased rate of division of primary cells consti-
tuting the tissue, that is, proliferation. Consequently,
proliferation has initially been regarded as the main
mechanism underlying ASM hyperplasia in asthmatics.
However, despite extensive research, the evidence for
ASM proliferation in asthmatics remains largely incon-
clusive. In some ex vivo studies [19,20], but not others
[21,22], asthmatic ASM showed increased proliferation
compared to non-asthmatics. More importantly, sev-
eral in vivo studies have failed to demonstrate prolifera-
tion [8,23]. Similarly, there is a lack of evidence to
suggest that ex vivo ASM from asthmatics has an
altered rate of survival. It therefore remains unclear
whether altered cell proliferation or survival contrib-
utes significantly to ASM hyperplasia in asthmatics, al-
though, in our opinion, this seems unlikely to be the
principal underlying mechanism.
Peripheral blood-derived mesenchymal progenitors
Fibrocytes are the only blood-derived mesenchymal pro-
genitors identified as a possible source of ASM in asthma.
They were first described by Bucala et al. in 1994 in a



















Figure 1 The potential origins of myofibroblast and ASM hyperplasia in asthmatic airways. Increased airway smooth muscle (ASM) and
myofibroblast cell numbers could result from recruitment of fibrocytes from the peripheral circulation to the airway tissue; or from differentiation
of tissue resident mesenchymal stem cells (MSCs); or from epithelial-mesenchymal transition (EMT) of epithelial cells. Additionally, pericytes may
also contribute to this process. To transform to functioning ASM or myofibroblasts, all these cells lose their non-mesenchymal markers and
acquire mesenchymal characteristics like increased α-SMA expression.
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ties [24]. Since then fibrocytes have gained increasing
prominence with emerging evidence of their involvement
in the aberrant tissue repair evident in a number of fi-
brotic lung disorders, including pulmonary hypertension,
idiopathic pulmonary fibrosis and asthma [25]. Fibrocytes
normally constitute 1% of the peripheral blood leukocytes
and express a wide range of hematopoietic stem cell, mye-
loid and mesenchymal markers, including CD34, CD11b,
CD13, CD45, CXCR4, CCR7, procollagen-I, vimentin and
α-smooth muscle actin [26]. After leaving the circulation
and once in any tissue, fibrocytes lose the expression
of their hematopoietic markers and gain mesenchymal
markers accentuated by transforming growth factor-β
(TGF-β) and endothelin-1, both of which are found at
increased levels in asthmatic airway tissues compared
to non-asthmatic tissue [27,28].
The first evidence of fibrocyte involvement in asthma
was described a decade ago. Schmidt and associates
showed, in a group of allergic asthmatics, an increase in
the number of cells co-expressing CD34, procollagen-I
mRNA, and α-smooth muscle actin in the sub-epithelium
following allergen exposure [29]. The authors also showed,
by labeling and tracking fibrocytes in an experimental
mouse model of allergic asthma, that fibrocytes are re-
cruited from the circulation after allergen exposure. In
a study connecting fibrocytes directly to remodeling,
Nihlberg et al. showed a clear correlation between the
thickness of the basement membrane and the number
of tissue fibrocytes in a small group of patients withsteroid-naïve mild asthma [30]. Wang et al. demonstrated
a relationship between peripheral blood fibrocyte number
and airflow obstruction [31]. The increased proliferation
of fibrocytes in asthmatics with chronic airflow obstruc-
tion has recently been linked to oxidative stress mediated
via up-regulation of the epidermal growth factor receptor
pathway [32]. The clearest evidence of the direct con-
tribution of fibrocytes to ASM hyperplasia in vivo was
presented by Saunders et al. [33]. They showed that, com-
pared to normal controls, severe refractory asthmatics
have an increased number of fibrocytes in the peripheral
circulation and also in the airway submucosa. More inter-
estingly, they demonstrated an increased number of
fibrocytes in the ASM bundle in asthmatics of all sever-
ities. It is important to note that despite the relatively large
number of subjects in this study (51 asthmatics and 33
healthy controls), the researchers failed to demonstrate
any link between fibrocytes and lung function.
Although the homing of fibrocytes to damaged tissues is
not fully understood, a few chemotactic pathways have
been identified and others suggested. Human fibrocytes
express several chemokine receptors, including CCR2,
CCR3, CCR5, CCR7 and CXCR4 [34]. In particular,
CXCR4 and its ligand, CXCL12, were proven to play an
important role in fibrocyte homing to the lung in a model
of bleomycin-induced pulmonary fibrosis [35]. IL-33,
which is increased in asthmatic airways and is related to
severity, has been shown to have a strong chemotactic and
proliferative effect on asthmatic fibrocytes compared to
healthy controls [36]. Given the epithelial origin of IL-33,
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from the circulation and subsequent sub-epithelial myo-
fibroblast accumulation but not specifically for fibrocyte
migration to the ASM bundle within the airway tissue.
In vitro, platelet-derived growth factor originating from
ASM, and CCL19 released by mast cells within the
ASM-bundle, can promote fibrocyte and myofibroblast
migration, respectively, towards the ASM [33,37].
Mesenchymal stem cells
Our knowledge and understanding of the role of mesen-
chymal stem cells (MSCs) in general remains relatively
limited. The research into the subject has been hindered
by many factors including the lack of a universally agreed
upon definition and the relative paucity of identifiable spe-
cific cell markers. MSCs lack hematopoietic and epithelial
markers and possess multiple other markers suggestive of
multi-lineage mesenchymal differentiation potential.
Tissue resident MSCs are an essential part of any con-
nective tissue and have important biological functions in
healing, repair and regeneration [38]. MSCs exist in
most tissues, including the bone marrow (also known as
bone marrow stromal cells or BMSC). BMSC have re-
cently generated much excitement and attention due to
their anti-inflammatory and immunomodulatory action.
In vivo, BMSC have clearly been shown to improve in-
flammation and, in vitro, BMSC were also proven to
inhibit most inflammatory cells [39]. Treatment with
BMSC has resulted in promising results in steroid-
resistant graft versus host disease and also in disease
models of inflammatory diseases [40]. With regard to
experimental use of BMSC in asthma, this has been
promising although only limited to animal and in vitro
studies [41]. Mainly in murine models of asthma, treat-
ment with BMSC reduced inflammation and airway re-
modeling [42,43].
In the lung, however, the role of resident MSCs is con-
troversial. There is some evidence to support the in-
volvement of lung MSCs in the pathogenesis of some
fibrotic lung conditions. Studies have shown that MSCs
undergo transformation into a myofibroblastic pheno-
type in premature infants, possibly contributing to the
pathogenesis of bronchopulmonary dysplasia, and in
allograft lungs, possibly assisting in the development of
bronchiolitis obliterans [44,45]. This suggests that lung
resident MSCs can potentially transform into a smooth
muscle phenotype and possibly contribute to ASM
hyperplasia in asthma although the evidence is lacking.
Bentley et al. showed increased numbers of MSCs in the
lung of an ovalbumin-sensitized mouse model following
aerosol challenge, although this was not linked to any of
the features of remodeling [46].
Pericytes are contractile cells normally wrapped around
the endothelium of most microvasculature. They havebeen found to fulfill both the multilineage and markers
criteria for MSCs and many nowadays argue that pericytes
could be the source of all MSCs. In kidney injury,
pericytes have been found to be a source of mesenchymal
contractile cells. Interestingly, pericytes might be involved
in ASM hyperplasia in asthma, although the evidence is
limited to only one report in the literature. In a murine
asthma model, upon aeroallergen exposure, pericytes seem
to detach from vasculature and migrate to the sub-
epithelium of the airway, with up-regulation of α-smooth
muscle actin [40].
To conclude, limited evidence seems to suggest that,
unlike BMSC, lung resident MSCs lack beneficial immu-
nomodulatory action and can even contribute to disease
pathogenesis. The cause of this difference and whether
lung resident MSCs contribute to the pathogenesis of re-
modeling in asthma remain to be answered.
Epithelial-mesenchymal transition
Epithelial-mesenchymal transition is a biological process
in which epithelial cells lose adhesion and acquire mes-
enchymal traits, including increased motility and migra-
tion, prolonged survival and enhanced extracellular
matrix proteins production. EMT, mediated mainly by
the action of TGF-β, is known to play a role in cell dif-
ferentiation during embryogenesis and also in cancer
proliferation and metastasis [47]. Moreover, EMT has
also been shown to contribute to the pathophysiology of
a number of fibrotic diseases, including idiopathic pul-
monary fibrosis.
The airway epithelium in asthma is fragile with re-
duced cell to cell adhesion possibly making EMT more
likely [48]. However, despite this, the evidence for the
significance of EMT in asthma remains weak. Heijink et
al. reported EMT in TGF-β–primed cultured human
bronchial epithelium when exposed to aeroallergens
[49]. In a murine model of asthma, Johnson et al. dem-
onstrated, through labeling of epithelial cells, clear evi-
dence of EMT in vivo after prolonged allergen exposure
[50]. Finally, Hackett and colleagues compared the ef-
fect of TGF-β on cultured bronchial epithelium from
eight asthmatics and nine non-asthmatics [51]. They
showed evidence of EMT throughout the epithelium in
the asthmatic group, while in the non-asthmatics the
changes were limited to the basal layer of cells. The lack
of in vivo data on EMT in asthma makes quantifying
the relative contribution of EMT to mesenchymal cell
population expansion very difficult.
Conclusion
The factors governing ASM and myofibroblast hyperpla-
sia in asthma are still not fully understood. Further hu-
man studies following experimental challenges or novel
interventions, that impact upon airway remodeling, such
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licensed therapy for severe asthma that applies thermal
energy to the airway wall via a bronchoscope. In early
animal studies and in humans receiving thermoplasty
prior to lung resection for cancer, ASM mass is re-
duced, suggesting that the improved exacerbation fre-
quency and health status following therapy in asthma
may be in part due to a reduction in ASM mass [52].
Importantly, to date this has not been confirmed in
asthma. How the airway responds to this thermal injury
might shed light not only upon the mechanism of ac-
tion of this therapy, but also provide insights into air-
way repair in response to injury. Such studies will help
to determine the relationship between these structural
changes and disordered airway function. As discussed,
the role of mesenchymal stem and progenitor cells in
airway smooth muscle remodeling in asthma is ob-
scure. There is a significant possibility that a degree of
heterogeneity exists among these cells with some hav-
ing immunomodulatory properties that ought to be
promoted and others having pro-remodeling properties
that ought to be suppressed, although this remains to
be proven. In conclusion, the last few decades have ad-
vanced greatly our understanding of the role of inflam-
mation in asthma. The challenge for the next decade is
to understand the mechanisms driving airway remodel-
ing, particularly increased ASM mass and its clinical
relevance, to inform the development of new therapies.
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